Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Stock Has Average Target Price of $10.00 According to Brokerages

Key Points

• Analysts hold a “Moderate Buy” consensus on Autolus Therapeutics, with seven analysts assigning one-year average price target of $10.00 versus the stock’s recent price of $1.69.
• Institutional investors own 72.83% of the company, with notable new or expanded positions from Syncona Portfolio, Alphabet, Armistice Capital and QRG Capital Management.
• Autolus exceeded quarterly expectations, reporting an adjusted loss of $0.15 per share versus the projected $0.21 loss and revenue of $45.69 million versus the $38.56 million estimate, though the company remains significantly unprofitable.

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) have received a consensus rating of "Moderate Buy" from the seven analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, three have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $10.00.

A number of brokerages have issued reports on AUTL. Weiss Ratings raised shares of Autolus Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, August 13th. Wall Street Zen raised Autolus Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday, August 16th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of Autolus Therapeutics in a report on Monday, August 3rd.

Institutional Trading of Autolus Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Syncona Portfolio Ltd bought a new position in Autolus Therapeutics in the 2nd quarter worth about $26,625,152. Alphabet Inc. purchased a new position in Autolus Therapeutics during the 2nd quarter valued at about $1,117,000. Armistice Capital LLC grew its holdings in Autolus Therapeutics by 12.2% during the 4th quarter. Armistice Capital LLC now owns 17,500,000 shares of the company's stock valued at $34,825,000 after buying an additional 1,900,000 shares in the last quarter. QRG Capital Management Inc. grew its holdings in Autolus Therapeutics by 67.7% during the 2nd quarter. QRG Capital Management Inc. now owns 18,325 shares of the company's stock valued at $29,000 after buying an additional 7,400 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. increased its position in shares of Autolus Therapeutics by 2.5% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 451,403 shares of the company's stock valued at $722,000 after buying an additional 11,197 shares during the period. 72.83% of the stock is currently owned by institutional investors.

Autolus Therapeutics Stock Performance

NASDAQ AUTL opened at $1.69 on Thursday. The company's 50 day moving average is $2.06 and its 200-day moving average is $1.74. Autolus Therapeutics has a 12-month low of $1.18 and a 12-month high of $2.58. The company has a quick ratio of 4.40, a current ratio of 4.89 and a debt-to-equity ratio of 1.04. The firm has a market cap of $449.82 million, a P/E ratio of -1.59 and a beta of 2.15.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.06. The company had revenue of $45.69 million for the quarter, compared to analysts' expectations of $38.56 million. Autolus Therapeutics had a negative net margin of 238.66% and a negative return on equity of 178.66%. Sell-side analysts predict that Autolus Therapeutics will post -0.75 earnings per share for the current year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing programmed T-cell therapies for the treatment of cancer. The company's platform is designed to genetically engineer T cells so they can recognize cancer targets, remain active in the body, and potentially reduce some limitations associated with conventional cell therapies.

Its lead product, obecabtagene autoleucel, is an autologous CAR T-cell therapy marketed in the United States as Aucatzyl.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.